1KDIGO Clinical Practice Guideline for Glomerulonephritis. ht- tp://www, kdigo, org/clinical_practice_guidelines/GN, php.
2Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospho- lipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med,2009,361 : 11-21.
3Menon S, Valentini RP. Membranous nephropathy in children: Clinical presentation and therapeutic approach. Pediatr Nephrol, 2010,25:1419-1428.
4Makker SP. Treatment of membranous nephropathy in children. Semin Nephrol, 2003,23 : 379-385.
5Cattran IX2, Alexopoulos E, Heering P, et al. Cyclosporin in idio pathic glomerular disease associated with the nephrotic syn drome.-Workshop recommendations. Kidney Int, 2007, 72:1429- 1447.
6Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous ne- phropathy. N Engl J Med, 1989,320:210-215.
7Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: A 1 year randomized controlled trial. Am J Kidney Dis,2008,52:699-705.
8Branten AJ, Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy.- A clinical trial with comparison to a historic control group treated with cyclo- phosphamide. Am J Kidney Dis, 2007,5(I = 248 256.
9Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int, 2008, 73: 117-125_.
10Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy A 2-year study. Clin J Am Soc Nephrol,2010,5..2188-2198.
